Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 195.83

-0.7%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Torben Noerup Nielsen who wrote (22446)	6/18/1998 8:00:00 AM
From: Henry Niman	Read Replies (1) of 32384

CNBC just did another report which was similar the the earlier report, except this time the clarified the SRGN acquisition and indicated that more than half of the acquisition price $37 million, was contingent on the ONTAK approval. Report again indicated that approval was not being granted at this time and future approval was contingent upon elimination of deficiencies. It sounds more like and administrative issue. The news reports generally are saying that SGRN received a "Complete Review" letter from the FDA. The only place that I have seen the letter called a "rejection" was on the Dow Jones report uploaded here and on MIS by guess who. The report at WSJ interactive is like all of the others which reports the news as a "Complete Review" letter. Has anyone else seen the Dow Jones report that uses the "Rejection" term?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next